A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2018
At a glance
- Drugs ACP 01 (Primary)
- Indications Peripheral ischaemia
- Focus Therapeutic Use
- Sponsors Hemostemix
- 19 Apr 2018 According to a Hemostemix Inc. media release, the FDA has approved the IND for ACP-01, and company will be enrolling subjects at 15-20 clinical trial sites in Canada and the United States over the next 6 months.
- 20 Dec 2017 According to a Hemostemix Inc. media release, the company has received a No Objection Letter from Health Canada for trials of ACP-01 for patients with critical limb ischemia.
- 06 Dec 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2022.